Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313260072> ?p ?o ?g. }
- W4313260072 endingPage "79" @default.
- W4313260072 startingPage "79" @default.
- W4313260072 abstract "The emergence and spread of Mycobacterium tuberculosis strains resistant to many or all anti-tuberculosis (TB) drugs require the development of new compounds both efficient and with minimal side effects. Structure-activity-toxicity relationships of such novel, structurally diverse compounds must be thoroughly elucidated before further development. Here, we present the aroylhydrazone compounds (3a and 3b) regarding their: (i) acute and subacute toxicity in mice; (ii) redox-modulating in vivo and in vitro capacity; (iii) pathomorphology in the liver, kidney, and small intestine tissue specimens; and (iv) intestinal permeability. The acute toxicity test showed that the two investigated compounds exhibited low toxicity by oral and intraperitoneal administration. Changes in behavior, food amount, and water intake were not observed during 14 days of the oral administration at two doses of 1/10 and 1/20 of the LD50. The histological examination of the different tissue specimens did not show toxic changes. The in vitro antioxidant assays confirmed the ex vivo results. High gastrointestinal tract permeability at all tested pH values were demonstrated for both compounds. To conclude, both compounds 3a and 3b are highly permeable with low toxicity and can be considered for further evaluation and/or lead optimization." @default.
- W4313260072 created "2023-01-06" @default.
- W4313260072 creator A5005445636 @default.
- W4313260072 creator A5028089894 @default.
- W4313260072 creator A5028775586 @default.
- W4313260072 creator A5031339028 @default.
- W4313260072 creator A5045167164 @default.
- W4313260072 creator A5046068719 @default.
- W4313260072 creator A5055163399 @default.
- W4313260072 creator A5067429447 @default.
- W4313260072 creator A5070723409 @default.
- W4313260072 creator A5088271096 @default.
- W4313260072 date "2022-12-26" @default.
- W4313260072 modified "2023-09-27" @default.
- W4313260072 title "In Vivo Toxicity, Redox-Modulating Capacity and Intestinal Permeability of Novel Aroylhydrazone Derivatives as Anti-Tuberculosis Agents" @default.
- W4313260072 cites W149769536 @default.
- W4313260072 cites W1964923689 @default.
- W4313260072 cites W1980792687 @default.
- W4313260072 cites W1992900987 @default.
- W4313260072 cites W2012801837 @default.
- W4313260072 cites W2020485499 @default.
- W4313260072 cites W2032865438 @default.
- W4313260072 cites W2039845745 @default.
- W4313260072 cites W2042464457 @default.
- W4313260072 cites W2050897300 @default.
- W4313260072 cites W2061617026 @default.
- W4313260072 cites W2065853716 @default.
- W4313260072 cites W2067184338 @default.
- W4313260072 cites W2101422765 @default.
- W4313260072 cites W2103007390 @default.
- W4313260072 cites W2115187133 @default.
- W4313260072 cites W2134368659 @default.
- W4313260072 cites W2138220389 @default.
- W4313260072 cites W2163970210 @default.
- W4313260072 cites W2165201727 @default.
- W4313260072 cites W2401977844 @default.
- W4313260072 cites W2519044800 @default.
- W4313260072 cites W2552840093 @default.
- W4313260072 cites W2563430249 @default.
- W4313260072 cites W2593436234 @default.
- W4313260072 cites W2609522315 @default.
- W4313260072 cites W2610549409 @default.
- W4313260072 cites W2797244022 @default.
- W4313260072 cites W2884946551 @default.
- W4313260072 cites W2914878893 @default.
- W4313260072 cites W2953482456 @default.
- W4313260072 cites W2964896979 @default.
- W4313260072 cites W2968953851 @default.
- W4313260072 cites W2972449690 @default.
- W4313260072 cites W2976082690 @default.
- W4313260072 cites W2999360216 @default.
- W4313260072 cites W3004885960 @default.
- W4313260072 cites W3034698724 @default.
- W4313260072 cites W3127973277 @default.
- W4313260072 cites W3164869506 @default.
- W4313260072 cites W4247088117 @default.
- W4313260072 cites W4282557375 @default.
- W4313260072 cites W4282916608 @default.
- W4313260072 cites W4294676331 @default.
- W4313260072 cites W622596276 @default.
- W4313260072 cites W3173868948 @default.
- W4313260072 doi "https://doi.org/10.3390/pharmaceutics15010079" @default.
- W4313260072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36678708" @default.
- W4313260072 hasPublicationYear "2022" @default.
- W4313260072 type Work @default.
- W4313260072 citedByCount "1" @default.
- W4313260072 countsByYear W43132600722023 @default.
- W4313260072 crossrefType "journal-article" @default.
- W4313260072 hasAuthorship W4313260072A5005445636 @default.
- W4313260072 hasAuthorship W4313260072A5028089894 @default.
- W4313260072 hasAuthorship W4313260072A5028775586 @default.
- W4313260072 hasAuthorship W4313260072A5031339028 @default.
- W4313260072 hasAuthorship W4313260072A5045167164 @default.
- W4313260072 hasAuthorship W4313260072A5046068719 @default.
- W4313260072 hasAuthorship W4313260072A5055163399 @default.
- W4313260072 hasAuthorship W4313260072A5067429447 @default.
- W4313260072 hasAuthorship W4313260072A5070723409 @default.
- W4313260072 hasAuthorship W4313260072A5088271096 @default.
- W4313260072 hasBestOaLocation W43132600721 @default.
- W4313260072 hasConcept C116263406 @default.
- W4313260072 hasConcept C142724271 @default.
- W4313260072 hasConcept C150903083 @default.
- W4313260072 hasConcept C178790620 @default.
- W4313260072 hasConcept C185592680 @default.
- W4313260072 hasConcept C202751555 @default.
- W4313260072 hasConcept C203014093 @default.
- W4313260072 hasConcept C207001950 @default.
- W4313260072 hasConcept C26291073 @default.
- W4313260072 hasConcept C2777056448 @default.
- W4313260072 hasConcept C2777882243 @default.
- W4313260072 hasConcept C2777975735 @default.
- W4313260072 hasConcept C2780512811 @default.
- W4313260072 hasConcept C2781069245 @default.
- W4313260072 hasConcept C2781071285 @default.
- W4313260072 hasConcept C29730261 @default.
- W4313260072 hasConcept C55493867 @default.
- W4313260072 hasConcept C71924100 @default.
- W4313260072 hasConcept C86803240 @default.